|
Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition.
|
Completed
|
DICLOFENAC POTASSIUM
|
BE
|
42856
|
Saudi Ajal
|
|
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial
|
Completed
|
Luspatercept (ACE 536)
|
3
|
ACE-536-B-THAL-001
|
King Khalid University Hospital (Riyadh)
|
|
"A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity ofArabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56Years and Above in Saudi Arabia"
|
Completed
|
Meningococcal Conjugate Vaccine (MenACWY-CRM) (Aramen)
|
3b
|
ARA/001/16
|
King Khalid University Hospital (Riyadh)
|
|
Intra Peritoneal Instillation of Ropivacaine with or without Dexmedetomidine for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy. A randomized controlled
|
Completed
|
Dexmedetomidine
|
2
|
version 4
|
King Abdullah Medical City (Makkah)
|
|
Vitamin D Status Correction and Validation of its Potential Clinical Utility through Discovery Proteomic Analysis
|
Completed
|
cholecalciferol
|
3
|
E-15-1667
|
King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh)
|
|
Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI)
|
Completed
|
Osimertinib (AZD9291)
|
3
|
D5160C00022
|
King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh)
|
|
A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Terminated
|
Osimertinib (AZD9291)
|
3
|
D5160C00007
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Randomized Trial of Influenza Vaccine to Reduce Adverse Vascular Events: A Pilot Study
|
Terminated
|
haemagglutinin (HA)/Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)
|
3
|
Version date Sep-3-2013
|
King Khalid University Hospital (Riyadh)
|
|
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study.
|
Completed
|
Doxorubicin
|
3
|
BA2011/03/04
|
King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah)
|
|
Phase 1 Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients with Retinal Disease due to MERTK Mutations
|
Completed
|
rAAV2-VMD2-hMERTK
|
1
|
rAAV2-VMD2-hMERTK
|
King Faisal Specialist Hospital and Research Center (Riyadh), King Khaled Eye Specialist Hospital (Riyadh)
|
